Clonal Hematopoiesis (CHIP) in Pulmonary Embolism and CTEPH: Evidence, Mechanisms, and Risk Stratification
International Journal of Molecular Sciences · 18.03.2026 · 27 (6) · 2750
DOI: 10.3390/ijms27062750 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.03.2026. Verfasst von Lukasz Szarpak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Pulmonary Embolism, Hypertension, Pulmonary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pulmonary embolism (PE) is biologically heterogeneous. Despite guideline-directed anticoagulation, a subset of patients develops recurrent venous thromboembolism, persistent exertional limitation, residual perfusion defects, and progression to chronic thromboembolic pulmonary disease (CTEPD) or chronic thromboembolic pulmonary hypertension (CTEPH). Conventional risk factors explain much of the index event but incompletely account for thrombus non-resolution and chronic sequelae. Clonal hematopoiesis of indeterminate potential (CHIP)—the age-associated expansion of hematopoietic clones carrying somatic mutations—defines a measurable thrombo-inflammatory endophenotype that is strongly genotype- and clone-size (variant allele frequency; VAF)-dependent. Across human studies, JAK2-CHIP and TET2-CHIP show the most consistent associations with VTE/PE, whereas isolated DNMT3A-CHIP is frequently neutral, and larger clones tend to confer stronger effects. Mechanistically, CHIP can bias myeloid cells toward inflammasome/IL-1β signaling and endothelial activation, increase monocyte tissue factor activity, and promote immunothrombosis with neutrophil extracellular trap (NET) formation. NET-rich thrombi may adopt a dense fibrin–DNA–histone architecture that resists endogenous fibrinolysis, favoring organization and persistence. CTEPH offers a translational window to interrogate this model because thrombotic material and deep phenotyping are accessible. We synthesize genotype- and VAF-resolved clinical and mechanistic evidence using a structured strength-of-evidence framework and propose a pragmatic phenotyping roadmap with testable predictions for prospective post-PE validation. CHIP testing in PE/CTEPH remains investigational and should not currently change standard care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
- Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
- Institute of Biological Sciences, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
ORCID-Profile: Lukasz Szarpak, Monika E Jach, Sebastian Radej, Michal Pruc
Zitieren
APA
Szarpak, L., Jach, M. E., Skoczylas, M., Radej, S., & Pruc, M. (2026). Clonal Hematopoiesis (CHIP) in Pulmonary Embolism and CTEPH: Evidence, Mechanisms, and Risk Stratification. International Journal of Molecular Sciences, 27(6), 2750. https://doi.org/10.3390/ijms27062750
Vancouver
Szarpak L, Jach ME, Skoczylas M, Radej S, Pruc M. Clonal Hematopoiesis (CHIP) in Pulmonary Embolism and CTEPH: Evidence, Mechanisms, and Risk Stratification. International Journal of Molecular Sciences. 2026;27(6):2750. doi:10.3390/ijms27062750
BibTeX
@article{Szarpak2026,
author = {Szarpak, Lukasz and Jach, Monika E and Skoczylas, Michal and Radej, Sebastian and Pruc, Michal},
title = {Clonal Hematopoiesis (CHIP) in Pulmonary Embolism and CTEPH: Evidence, Mechanisms, and Risk Stratification},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2750},
doi = {10.3390/ijms27062750}
}
EUVIMED